Consecutive Dexamethasone-Fluocinolone Acetonide Therapy in Non-Infectious Uveitic Macular Edema: Real-World Outcomes.

Dexamethasone implantation resulted in rapid and significant improvements in BCVA and central macular thickness, with peak effects observed at approximately 4 weeks; however, anatomical benefits were often time-limited, necessitating reinjection.

Eyes receiving dexamethasone followed by fluocinolone acetonide achieved effective long-term disease control and a reduced treatment burden.

Adverse events, including intraocular pressure elevations, were transient and manageable.